Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Change in Account Payables (2017 - 2025)

Dianthus Therapeutics (DNTH) has 7 years of Change in Account Payables data on record, last reported at $3.0 million in Q3 2025.

  • For Q3 2025, Change in Account Payables fell 46.84% year-over-year to $3.0 million; the TTM value through Sep 2025 reached $6.9 million, down 8.53%, while the annual FY2024 figure was $8.2 million, 1139.18% up from the prior year.
  • Change in Account Payables reached $3.0 million in Q3 2025 per DNTH's latest filing, down from $3.1 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $5.7 million in Q3 2024 and bottomed at -$4.7 million in Q1 2023.
  • Average Change in Account Payables over 4 years is $842933.3, with a median of $1.4 million recorded in 2022.
  • Peak YoY movement for Change in Account Payables: crashed 438.27% in 2023, then skyrocketed 631.05% in 2024.
  • A 4-year view of Change in Account Payables shows it stood at -$339000.0 in 2022, then surged by 572.86% to $1.6 million in 2023, then skyrocketed by 42.23% to $2.3 million in 2024, then skyrocketed by 31.75% to $3.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Account Payables were $3.0 million in Q3 2025, $3.1 million in Q2 2025, and -$1.5 million in Q1 2025.